Stockreport

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Complete resolution of diplopia in 51% of patients treated Q [Read more]